Matsuda Masaru — SEC insider filings

SEC reporting owner CIK 1798679. 36 insider filings on record with FilingPulse; latest filed 2026-11-04.

Transaction summary — filings shown

Covers all 36 filings on record, filed 2020-09-04 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Arcutis Biotherapeutics, Inc. (ARQT)EVP, Chief Legal Officer322 legs · 5,657 sh · $18,54338 legs · 220,560 sh · $4,860,30126
HALOZYME THERAPEUTICS, INC. (HALO)SVP, General Counsel4——14

Insider filings — Matsuda Masaru

FiledFormIssuerReported transactionsSource
2026-11-044Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 1,219 @ $31.86 · Option exercise (M): 40,000 @ $3.64 · Sale (S): 40,000 @ $34.32 · Option exercise (M): 40,000 (derivative) @ $0EDGAR
2026-09-184Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 3,674 @ $25.00EDGAR
2026-09-104Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 9,989 @ $25.03EDGAR
2026-08-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 1,230 @ $26.12EDGAR
2026-05-064Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 7,372 @ $23.27 · Sale (S): 884 @ $23.61EDGAR
2026-03-034Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 37,000 @ $0 · Sale (S): 3,325 @ $27.95 · Sale (S): 6,553 @ $25.16 · Sale (S): 193 @ $25.91 · Sale (S): 1,987 @ $25.70 · Grant/award (A): 97,000 (derivative) @ $0EDGAR
2026-02-044Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 7,983 @ $25.50 · Sale (S): 8,562 @ $24.97 · Sale (S): 19,379 @ $25.24 · Sale (S): 4,714 @ $25.63EDGAR
2025-12-034Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 1,657 @ $30.23EDGAR
2025-11-214Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 989 @ $27.95 · Sale (S): 1,561 @ $28.50EDGAR
2025-11-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 7,165 @ $24.71 · Sale (S): 43 @ $25.40EDGAR
2025-09-084Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 36,130 @ $16.16EDGAR
2025-08-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 6,330 @ $14.33EDGAR
2025-05-294Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 1,800 @ $13.78EDGAR
2025-05-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 5,030 @ $15.20EDGAR
2025-03-044Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 34,000 @ $0 · Sale (S): 3,263 @ $13.03 · Grant/award (A): 89,000 (derivative) @ $0EDGAR
2025-02-044Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 8,338 @ $12.70EDGAR
2024-12-034Arcutis Biotherapeutics, Inc. (ARQT)Purchase (P): 4,000 @ $1.69 · Purchase (P): 1,657 @ $7.11EDGAR
2024-11-194Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,775 @ $9.68EDGAR
2024-11-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 5,015 @ $8.68EDGAR
2024-08-054Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 5,220 @ $9.02EDGAR
2024-05-294Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,775 @ $9.01EDGAR
2024-05-034Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 5,016 @ $8.74EDGAR
2024-03-064Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 3,760 @ $11.12EDGAR
2024-02-154Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 74,000 · Grant/award (A): 17,650 · Grant/award (A): 27,900 · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 35,300 (derivative) · Disposition to issuer (D): 55,800 (derivative)EDGAR
2024-01-174Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 28,000 @ $0 · Grant/award (A): 176,000 (derivative) @ $0EDGAR
2023-11-214Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,850 @ $1.98EDGAR
2023-06-024Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,830 @ $7.80 · Grant/award (A): 1,463 @ $6.38EDGAR
2023-03-064Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 1,416 @ $15.82 · Sale (S): 18 @ $16.52 · Grant/award (A): 21,000 @ $0 · Grant/award (A): 55,800 (derivative) @ $0EDGAR
2022-11-224Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,720 @ $18.19EDGAR
2022-06-024Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,875 @ $0 · Sale (S): 1,795 @ $19.73EDGAR
2022-03-074Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 13,300 @ $0 · Grant/award (A): 35,300 (derivative) @ $0EDGAR
2022-01-054Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 185,000 (derivative) @ $0EDGAR
2021-09-074HALOZYME THERAPEUTICS, INC. (HALO)Option exercise (M): 6,883 @ $0 · Tax withholding (F): 3,412 @ $42.22 · Option exercise (M): 6,883 (derivative) @ $0EDGAR
2021-02-174HALOZYME THERAPEUTICS, INC. (HALO)Grant/award (A): 23,311 (derivative) @ $0 · Grant/award (A): 13,544 (derivative) @ $0EDGAR
2021-02-124HALOZYME THERAPEUTICS, INC. (HALO)Option exercise (M): 6,257 @ $0 · Tax withholding (F): 3,203 @ $50.60 · Option exercise (M): 4,129 @ $0 · Tax withholding (F): 2,047 @ $49.84 · Option exercise (M): 6,257 (derivative) @ $0 · Option exercise (M): 4,129 (derivative) @ $0EDGAR
2020-09-044HALOZYME THERAPEUTICS, INC. (HALO)Option exercise (M): 6,884 @ $0 · Tax withholding (F): 2,380 @ $27.70 · Option exercise (M): 6,884 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1798679 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs